Therapeutics Inc. is a privately-owned, emerging biopharmaceutical company dedicated to the development of life-saving therapeutics to combat treatment-resistant cancers. It is founded on a uniquely positioned breakthrough technology, DNA Bait, which deals with DNA repair pathways as a global target, instead of targeting a key gene-protein whatever its biological importance and clinical relevance. This is an innovative approach in conjunction with radio - and chemotherapies for cost effective and efficient therapeutics focused on highly unmet medical needs. Progression of cancer is associated with the deregulation of many genes involved in multiple pathways responsible for controlling cell growth and differentiation including cell cycle, programmed cell death, intra - and intercellular communication, and DNA repair processes. Discovery and development of new drugs based on the knowledge of DNA damage sensing, signaling and repair opens an innovative approach, improving the efficacy of chemotherapeutic drugs and radiotherapy, and thus addressing unmet medical needs in cancer treatment. Developing the cutting-edge technologies and novel medicines that will significantly improve the treatment of cancer by inhibiting DNA repair related processes, overcoming cancer cell resistance to therapy and in this way achieving better clinical outcomes. We have named our premier innovative strategy to ensure this: DNA bait DNA Therapeutics aims to strengthen and fully exploit the utmost from DNA bait, a pathway targeting and mechanism-oriented approach, and to add progressively other anticancer weapons to its armamentarium, both conventional and innovative, in order to develop a multiple product pipeline for as many tumors as possible wherever there are high unmet medical needs. DNA Therapeutics will focus on business-driven drug development. We will optimize the use of product co-development with existing corporate players who will participate in the financing of late stage clinical trials, production, marketing and commercialization, at least at our initial phase. Entering the biopharmaceutical arena thanks to a proprietary cutting edged DNA bait technology and strong translational research support. Bringing this paradigm-shift approach to success by validating the DNA bait concept in the clinic and by leveraging its financial consequences, Thus becoming a fully fledged and highly successful biopharmaceutical company, with a well balanced and sustained pipeline; Playing a key role in the advancement of therapies against cancer and at a future stage other biologically related diseases.

Карта сайта

Информационный сайт